Evidence map›Paper›PMID 23842546›Full record

ArticleNature communications2013

Landscape of the mitochondrial Hsp90 metabolome in tumours.

Young Chan Chae, Alessia Angelin, Sofia Lisanti, Andrew V Kossenkov, Kaye D Speicher, Huan Wang, James F Powers, Arthur S Tischler, Karel Pacak, Stephanie Fliedner and 6 more

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Nature communications, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 109 papers.

0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

109 citing papers in PubMed, 165 citations in OpenAlex.

  1. The mitochondrial chaperone HSPD1 folds MTHFD2 independently of its co-chaperone HSPE1.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. HSP90 multi-functionality in cancer.Frontiers in immunology · 2024
    Review
  11. IFI27 Integrates Succinate and Fatty Acid Oxidation to Promote Adipocyte Thermogenic Adaption.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

49 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Young Chan ChaeProstate Cancer Discovery and Development Program, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.
Alessia Angelin
Sofia Lisanti
Andrew V Kossenkov
Kaye D Speicher
Huan Wang
James F Powers
Arthur S Tischler
Karel Pacak
Stephanie Fliedner
Ryan D Michalek
Edward D Karoly
Douglas C Wallace
Lucia R Languino
David W Speicher
Dario C Altieri
The Wistar Institute · USChildren's Hospital of Philadelphia · USEunice Kennedy Shriver National Institute of Child Health and Human Development · USMetabolon (United States) · USTufts Medical Center · USSidney Kimmel Cancer Center · US

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9M
Diagnosis, Pathophysiology And Molecular Biology of Pheochromocytoma and ParagangliomaZIAHD008735 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI PACAK, KAREL · 2009 to 2024
$28.4M
Role of Runx2 in prostate tumorigenesis and metastasisP01CA140043 · NCI · WISTAR INSTITUTE · PI ALTIERI, DARIO C · 2010 to 2021
$12.2M
MITOCHONDRIAL INBORN ERRORS OF METABOLISMR01NS021328 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI WALLACE, DOUGLAS C · 1985 to 2017
$6.5M
CONTROL OF APOPTOSIS IN CANCER BY SURVIVINR01CA078810 · NCI · YALE UNIVERSITY · PI ALTIERI, DARIO C · 1998 to 2017
$5.5M
Molecular Pathology of Vascular InjuryR37HL054131 · NHLBI · WISTAR INSTITUTE · PI ALTIERI, DARIO C · 2004 to 2013
$3.1M
Rational Design and Clinical Development of Shepherdin: A Novel Anti-Cancer AgentR01CA118005 · NCI · WISTAR INSTITUTE · PI ALTIERI, DARIO C · 2009 to 2013
$1.7M
MOLECULAR PATHOLOGY OF VASCULAR INJURYR01HL054131 · NHLBI · YALE UNIVERSITY · PI ALTIERI, DARIO C. · 1994 to 2003
$1.0M
NCI NIH HHS CA010815NCI NIH HHS CA118005NCI NIH HHS CA140043NCI NIH HHS CA78810NCI NIH HHS P01 CA140043NCI NIH HHS P30 CA010815NCI NIH HHS R01 CA078810NCI NIH HHS R01 CA118005NHLBI NIH HHS HL54131NHLBI NIH HHS R01 HL054131NHLBI NIH HHS R37 HL054131NINDS NIH HHS NS021328NINDS NIH HHS R01 NS021328
6 · The paper itself

Abstract

Reprogramming of tumour cell metabolism contributes to disease progression and resistance to therapy, but how this process is regulated on the molecular level is unclear. Here we report that heat shock protein 90-directed protein folding in mitochondria controls central metabolic networks in tumour cells, including the electron transport chain, citric acid cycle, fatty acid oxidation, amino acid synthesis and cellular redox status. Specifically, mitochondrial heat shock protein 90, but not cytosolic heat shock protein 90, binds and stabilizes the electron transport chain Complex II subunit succinate dehydrogenase-B, maintaining cellular respiration under low-nutrient conditions, and contributing to hypoxia-inducible factor-1α-mediated tumorigenesis in patients carrying succinate dehydrogenase-B mutations. Thus, heat shock protein 90-directed proteostasis in mitochondria regulates tumour cell metabolism, and may provide a tractable target for cancer therapy.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsAntineoplastic AgentsBrain NeoplasmsCarcinogenesisCell Line, TumorGlioblastomaGuanidinesHSP90 Heat-Shock ProteinsHumansHypoxia-Inducible Factor 1, alpha SubunitLactams, MacrocyclicMetabolomeMiceMitochondriaMitochondrial ProteinsAntineoplastic Agentsgamitrinib-G4GuanidinesHIF1A protein, humanHSP90 Heat-Shock ProteinsHypoxia-Inducible Factor 1, alpha SubunitLactams, MacrocyclicMitochondrial ProteinsSDHB protein, humanSuccinate DehydrogenaseTRAP1 protein, human

Identifiers

PMID23842546
PMCPMC3732457
OpenAlexW2015644600

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.